Mga Batayang Estadistika
| LEI | 549300NUBWKJMNMQ3287 |
| CIK | 1180145 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Cardiovascular Systems Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| May 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 000-52082 CARDIOVASCULAR SYSTEMS, INC. (Exact name of registrant as specifi |
|
| May 1, 2023 |
As filed with the Securities and Exchange Commission on May 1, 2023 As filed with the Securities and Exchange Commission on May 1, 2023 Registration No. |
|
| May 1, 2023 |
As filed with the Securities and Exchange Commission on May 1, 2023 As filed with the Securities and Exchange Commission on May 1, 2023 Registration No. |
|
| May 1, 2023 |
As filed with the Securities and Exchange Commission on May 1, 2023 S-8 POS 1 tm2313791d8s8pos.htm S-8 POS As filed with the Securities and Exchange Commission on May 1, 2023 Registration No. 333-261176 Registration No. 333-221651 Registration No. 333-208137 Registration No. 333-205578 Registration No. 333-200214 Registration No. 333-197350 Registration No. 333-197348 Registration No. 333-189858 Registration No. 333-189856 Registration No. 333-182669 Registration |
|
| May 1, 2023 |
As filed with the Securities and Exchange Commission on May 1, 2023 As filed with the Securities and Exchange Commission on May 1, 2023 Registration No. |
|
| May 1, 2023 |
As filed with the Securities and Exchange Commission on May 1, 2023 S-8 POS 1 tm2313791d9s8pos.htm S-8 POS As filed with the Securities and Exchange Commission on May 1, 2023 Registration No. 333-261176 Registration No. 333-221651 Registration No. 333-208137 Registration No. 333-205578 Registration No. 333-200214 Registration No. 333-197350 Registration No. 333-197348 Registration No. 333-189858 Registration No. 333-189856 Registration No. 333-182669 Registration |
|
| May 1, 2023 |
As filed with the Securities and Exchange Commission on May 1, 2023 As filed with the Securities and Exchange Commission on May 1, 2023 Registration No. |
|
| May 1, 2023 |
As filed with the Securities and Exchange Commission on May 1, 2023 As filed with the Securities and Exchange Commission on May 1, 2023 Registration No. |
|
| May 1, 2023 |
As filed with the Securities and Exchange Commission on May 1, 2023 S-8 POS 1 tm2313791d13s8pos.htm S-8 POS As filed with the Securities and Exchange Commission on May 1, 2023 Registration No. 333-261176 Registration No. 333-221651 Registration No. 333-208137 Registration No. 333-205578 Registration No. 333-200214 Registration No. 333-197350 Registration No. 333-197348 Registration No. 333-189858 Registration No. 333-189856 Registration No. 333-182669 Registration |
|
| May 1, 2023 |
As filed with the Securities and Exchange Commission on May 1, 2023 As filed with the Securities and Exchange Commission on May 1, 2023 Registration No. |
|
| May 1, 2023 |
As filed with the Securities and Exchange Commission on May 1, 2023 As filed with the Securities and Exchange Commission on May 1, 2023 Registration No. |
|
| May 1, 2023 |
As filed with the Securities and Exchange Commission on May 1, 2023 As filed with the Securities and Exchange Commission on May 1, 2023 Registration No. |
|
| May 1, 2023 |
As filed with the Securities and Exchange Commission on May 1, 2023 S-8 POS 1 tm2313791d2s8pos.htm S-8 POS As filed with the Securities and Exchange Commission on May 1, 2023 Registration No. 333-261176 Registration No. 333-221651 Registration No. 333-208137 Registration No. 333-205578 Registration No. 333-200214 Registration No. 333-197350 Registration No. 333-197348 Registration No. 333-189858 Registration No. 333-189856 Registration No. 333-182669 Registration |
|
| May 1, 2023 |
As filed with the Securities and Exchange Commission on May 1, 2023 S-8 POS 1 tm2313791d3s8pos.htm S-8 POS As filed with the Securities and Exchange Commission on May 1, 2023 Registration No. 333-261176 Registration No. 333-221651 Registration No. 333-208137 Registration No. 333-205578 Registration No. 333-200214 Registration No. 333-197350 Registration No. 333-197348 Registration No. 333-189858 Registration No. 333-189856 Registration No. 333-182669 Registration |
|
| May 1, 2023 |
As filed with the Securities and Exchange Commission on May 1, 2023 As filed with the Securities and Exchange Commission on May 1, 2023 Registration No. |
|
| May 1, 2023 |
As filed with the Securities and Exchange Commission on May 1, 2023 As filed with the Securities and Exchange Commission on May 1, 2023 Registration No. |
|
| May 1, 2023 |
As filed with the Securities and Exchange Commission on May 1, 2023 S-8 POS 1 tm2313791d14s8pos.htm S-8 POS As filed with the Securities and Exchange Commission on May 1, 2023 Registration No. 333-261176 Registration No. 333-221651 Registration No. 333-208137 Registration No. 333-205578 Registration No. 333-200214 Registration No. 333-197350 Registration No. 333-197348 Registration No. 333-189858 Registration No. 333-189856 Registration No. 333-182669 Registration |
|
| May 1, 2023 |
As filed with the Securities and Exchange Commission on May 1, 2023 S-8 POS 1 tm2313791d21s8pos.htm FORM S-8 POS As filed with the Securities and Exchange Commission on May 1, 2023 Registration No. 333-261176 Registration No. 333-221651 Registration No. 333-208137 Registration No. 333-205578 Registration No. 333-200214 Registration No. 333-197350 Registration No. 333-197348 Registration No. 333-189858 Registration No. 333-189856 Registration No. 333-182669 Registr |
|
| May 1, 2023 |
As filed with the Securities and Exchange Commission on May 1, 2023 As filed with the Securities and Exchange Commission on May 1, 2023 Registration No. |
|
| May 1, 2023 |
As filed with the Securities and Exchange Commission on May 1, 2023 As filed with the Securities and Exchange Commission on May 1, 2023 Registration No. |
|
| May 1, 2023 |
As filed with the Securities and Exchange Commission on May 1, 2023 As filed with the Securities and Exchange Commission on May 1, 2023 Registration No. |
|
| April 27, 2023 |
AMENDED AND RESTATED CARDIOVASCULAR SYSTEMS, INC. Article I Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF CARDIOVASCULAR SYSTEMS, INC. (Delaware) *** Article I Offices Section 1.1 Registered Office. The corporation shall maintain a registered office and registered agent in the State of Delaware. The registered office and/or registered agent of the corporation may be changed from time to time by action of the board of directors. Section 1.2 |
|
| April 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 27, 2023 Date of Report (Date of earliest event reported) CARDIOVASCULAR SYSTEMS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 000-52082 41-1698056 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| April 27, 2023 |
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION CARDIOVASCULAR SYSTEMS, INC. ARTICLE I Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CARDIOVASCULAR SYSTEMS, INC. *** ARTICLE I The name of the corporation (hereinafter called the “Corporation”) is Cardiovascular Systems, Inc. ARTICLE II The address of the registered office of the Corporation in the State of Delaware is Corporation Trust Center, 1209 Orange Street, in the City of Wilmington, County of New Castle, 198 |
|
| April 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 12, 2023 CARDIOVASCULAR SYSTEMS, INC. (Exact Name of registrant as specified in its charter) Delaware 000-52082 41-1698056 (State or other jurisdiction of incorporation) (Commis |
|
| April 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| April 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| March 23, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ D |
|
| March 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| March 13, 2023 |
Exhibit 107 Calculation of Filing Fee Table SCHEDULE 14A (Form Type) Cardiovascular Systems, Inc. |
|
| March 13, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ D |
|
| February 14, 2023 |
CSII / Cardiovascular Systems Inc / BROWN CAPITAL MANAGEMENT LLC Passive Investment SC 13G/A 1 fp0081785-1sc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 10)* Cardiovascular Systems, Inc. (Name of Issuer) Common Stock, $0.001 Par Value Per Share (Title of Class of Securities) 14 |
|
| February 9, 2023 |
CSII / Cardiovascular Systems Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: Cardiovascular Systems Inc. Title of Class of Securities: Common Stock CUSIP Number: 141619106 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| February 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 00 |
|
| February 9, 2023 |
Exhibit 10.2 Final Version FIRST AMENDED AND RESTATED ACQUISITION OPTION AGREEMENT by and among CARDIOVASCULAR SYSTEMS, INC. CHANSU VASCULAR TECHNOLOGIES, LLC, and THE MEMBERS OF CHANSU VASCULAR TECHNOLOGIES, LLC, dated as of December 30, 2022 TABLE OF CONTENTS ARTICLE I Definitions................................................................................................................... 4 |
|
| February 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2023 CARDIOVASCULAR SYSTEMS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 000-52082 41-1698056 (State or Other Jurisdiction of Incorporation) (Comm |
|
| February 9, 2023 |
, by and between the Company and Chansu Vascular Technologies, LLC. Exhibit 10.3 EXECUTION VERSION PRODUCT DEVELOPMENT AGREEMENT This Product Development Agreement (this “Agreement”), effective as of January 29, 2021 (the “Effective Date”), is made by and between Cardiovascular Systems, Inc., a Delaware corporation with its principal place of business at 1225 Old Highway 8 NW, Saint Paul, Minnesota 55112 (“CSI”), and Chansu Vascular Technologies, LLC, a Delaware l |
|
| February 9, 2023 |
CARDIOVASCULAR SYSTEMS, INC. REPORTS FISCAL 2023 SECOND QUARTER FINANCIAL RESULTS Exhibit 99.1 CARDIOVASCULAR SYSTEMS, INC. REPORTS FISCAL 2023 SECOND QUARTER FINANCIAL RESULTS St. Paul, Minn., February 8, 2023 – Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today reported financial results for its second quarter, en |
|
| February 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| February 9, 2023 |
— Private Securities Litigation Reform Act of 1995 — A Caution Concerning Forward-Looking Statements Exhibit 99.1 News Release Abbott to Acquire Cardiovascular Systems, Inc. •Abbott will gain an innovative, complementary solution in treating vascular disease through CSI's leading atherectomy system, which prepares vessels for angioplasty or stenting to restore blood flow •CSI's offering will support Abbott's ability to provide better care for patients with peripheral and coronary artery disease A |
|
| February 9, 2023 |
Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER AMONG ABBOTT LABORATORIES, COBRA ACQUISITION CO. AND CARDIOVASCULAR SYSTEMS, INC. DATED AS OF FEBRUARY 8, 2023 TABLE OF CONTENTS ARTICLE I DEFINED TERMS 1 Section 1.1 Certain Defined Terms 1 Section 1.2 Additional Defined Terms 14 Section 1.3 Interpretation 15 ARTICLE II THE MERGER AND CERTAIN RELATED MATTERS 16 Section 2.1 The Merger 16 S |
|
| February 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2023 CARDIOVASCULAR SYSTEMS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 000-52082 41-1698056 (State or Other Jurisdiction of Incorporation) (Comm |
|
| February 9, 2023 |
Exhibit 10.1 Execution Version LOAN AGREEMENT This LOAN AGREEMENT (this “Agreement”), dated as of December 30, 2022 (the “Closing Date”), is between CHANSU VASCULAR TECHNOLOGIES, LLC, a Delaware limited liability company (the “Borrower”) and CARDIOVASCULAR SYSTEMS, INC., a Delaware corporation (together with its successors and assigns, the “Lender”). The parties hereto agree as follows: ARTICLE I |
|
| January 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2022 CARDIOVASCULAR SYSTEMS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 000-52082 41-1698056 (State or Other Jurisdiction of Incorporation) (Com |
|
| November 10, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2022 CARDIOVASCULAR SYSTEMS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 000-52082 41-1698056 (State or Other Jurisdiction of Incorporation) (Comm |
|
| November 10, 2022 |
CSII / Cardiovascular Systems Inc / BROWN CAPITAL MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 9)* Cardiovascular Systems, Inc. (Name of Issuer) Common Stock, $0.001 Par Value Per Share (Title of Class of Securities) 141619106 (CUSIP Number) Eddie C. Br |
|
| November 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2022 CARDIOVASCULAR SYSTEMS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 000-52082 41-1698056 (State or Other Jurisdiction of Incorporation) (Comm |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0 |
|
| November 3, 2022 |
?2022 Cardiovascular Systems, Inc. All Rights Reserved. Q1 FY23 Earnings Supplement November 3, 2022 Safe Harbor This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Report Act of 1995, which are provided under the protection of the safe harbor for forward-looking statements provided by that Act. For example, statements in this presentation |
|
| November 3, 2022 |
Exhibit 99.1 CARDIOVASCULAR SYSTEMS, INC. REPORTS FISCAL 2023 FIRST QUARTER FINANCIAL RESULTS Conference Call Scheduled for Today, November 3, 2022, at 8:00 a.m. CT (9:00 a.m. ET) ?Revenues of $59.7 million increased 2.2% compared to first quarter last year ?Management reiterates fiscal 23 revenue guidance of $255 million to $265 million, representing 8% to 12% growth St. Paul, Minn., November 3, |
|
| October 26, 2022 |
DEFR14A 1 def14a-2022amendedfullproxy.htm DEFR14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant þ Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commiss |
|
| September 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| September 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| August 18, 2022 |
Consulting Agreement, dated July 1, 2022, by and between the Company and David Whitescarver. Exhibit 10.56 CONSULTING AGREEMENT EFFECTIVE DATE: July 1, 2022 PARTIES: Cardiovascular Systems, Inc. (?CSI?) 1225 Old Highway 8 NW St. Paul, MN 55112 David Whitescarver (?Consultant?) [ADDRESS REDACTED] RECITAL: CSI and Consultant desire to enter into an arrangement by which Consultant will provide consulting services to CSI pursuant to the terms and conditions contained in this Agreement. AGREEM |
|
| August 18, 2022 |
Director Compensation Arrangements. Exhibit 10.3 FISCAL 2023 DIRECTOR COMPENSATION ARRANGEMENTS For the 12 month period ending June 30, 2023, each non-employee director of Cardiovascular Systems, Inc. will receive the following compensation: ? Retainers of $50,000 for service as a Board member; $22,000 for service as the chair of the Audit committee; $20,000 for service as a chair of a Board committee other than the Audit committee; |
|
| August 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-52082 CARDIOVASCULAR SYSTEMS, INC. (Exact name of registrant as speci |
|
| August 18, 2022 |
Exhibit 10.57 RESTRICTED STOCK AGREEMENT PERFORMANCE-BASED VESTING (REVENUE GROWTH) CARDIOVASCULAR SYSTEMS, INC. 2017 EQUITY INCENTIVE PLAN CARDIOVASCULAR SYSTEMS, INC., a Delaware corporation (the ?Company?) has engaged Morgan Stanley Smith Barney LLC (?MSSB?) to maintain an online system to provide secure account access to participants receiving grants (each, a ?Participant?) under the Company?s |
|
| August 18, 2022 |
Executive Officer Bonus Plan and Equity Compensation. Exhibit 10.2 FISCAL 2023 EXECUTIVE OFFICER BONUS PLAN AND EQUITY COMPENSATION Bonus Plan For the 12-month period ending June 30, 2023, each executive officer is eligible to receive cash incentive compensation pursuant to the Fiscal 2023 Executive Officer Bonus Plan (the ?Bonus Plan?), based on the Company?s achievement of revenue and adjusted EBITDA financial goals for such period. Adjusted EBITDA |
|
| August 18, 2022 |
Separation Agreement, dated June 30, 2022, by and between the Company and David Whitescarver. Exhibit 10.55 June 30, 2022 Via Email Personal and Confidential David Whitescarver [ADDRESS REDACTED] Re: Separation Agreement and Release Dear David: As you know, your retirement will be effective and your employment with Cardiovascular Systems, Inc. (?CSI?) will end effective at the close of business on June 30, 2022 (the ?Separation Date?), due to your voluntary resignation. The purpose of this |
|
| August 18, 2022 |
Exhibit 10.58 RESTRICTED STOCK AGREEMENT PERFORMANCE-BASED VESTING (TOTAL STOCKHOLDER RETURN) CARDIOVASCULAR SYSTEMS, INC. 2017 EQUITY INCENTIVE PLAN CARDIOVASCULAR SYSTEMS, INC., a Delaware corporation (the ?Company?) has engaged Morgan Stanley Smith Barney LLC (?MSSB?) to maintain an online system to provide secure account access to participants receiving grants (each, a ?Participant?) under the |
|
| August 18, 2022 |
Separation Agreement, dated June 6, 2022, by and between the Company and Rhonda Robb. Exhibit 10.54 June 6, 2022 Via Email Personal and Confidential To: Rhonda Robb Re: Separation Agreement and Release Dear Rhonda: As you know, your employment with Cardiovascular Systems, Inc. (?CSI?) will end effective at the close of business on June 6, 2022 (the ?Separation Date). The purpose of this Separation Agreement and Release letter (?Agreement?) is to set forth the Salary Continuation Be |
|
| August 3, 2022 |
Capital Markets Day August 3, 2022 Welcome Jack Nielsen Vice President, Investor Relations & Corporate Communications Q4 FY22 Financial Results Capital Markets Day – August 3, 2022 Company Overview Scott R. |
|
| August 3, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2022 CARDIOVASCULAR SYSTEMS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 000-52082 41-1698056 (State or Other Jurisdiction of Incorporation) (Commis |
|
| August 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2022 CARDIOVASCULAR SYSTEMS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 000-52082 41-1698056 (State or Other Jurisdiction of Incorporation) (Commis |
|
| August 3, 2022 |
CARDIOVASCULAR SYSTEMS, INC. REPORTS FISCAL 2022 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS Exhibit 99.1 CARDIOVASCULAR SYSTEMS, INC. REPORTS FISCAL 2022 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS Webcast Scheduled for Tomorrow, August 3, 2022, at 9:00 a.m. CT (10:00 a.m. ET) •Revenues of $62.5 million increased 11% sequentially compared to third quarter this year and decreased 12% compared to fourth quarter last year •Management provides fiscal 23 revenue guidance of $255 million to |
|
| August 3, 2022 |
©2022 Cardiovascular Systems, Inc. All Rights Reserved. Q4 FY22 Earnings Supplement August 2, 2022 Safe Harbor This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Report Act of 1995, which are provided under the protection of the safe harbor for forward-looking statements provided by that Act. For example, statements in this presentation re |
|
| July 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 21, 2022 CARDIOVASCULAR SYSTEMS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 000-52082 41-1698056 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| June 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2022 CARDIOVASCULAR SYSTEMS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 000-52082 41-1698056 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| May 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM SD SPECIALIZED DISCLOSURE REPORT CARDIOVASCULAR SYSTEMS, INC. |
|
| May 27, 2022 |
Exhibit 1.01 CONFLICT MINERALS REPORT For the reporting period from January 1, 2021 to December 31, 2021 Cardiovascular Systems, Inc. Cardiovascular Systems, Inc. (the ?Company,? ?we,? ?us,? ?our,? or ?CSI??), based in St. Paul, Minnesota, is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease. The Company?s Orbital Ath |
|
| May 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-5 |
|
| May 5, 2022 |
Fiscal 2022 Second Half Bonus Plan. Exhibit 10.1 FISCAL 2022 SECOND HALF BONUS PLAN For the 6-month period ending June 30, 2022, each executive officer is eligible to receive cash incentive compensation pursuant to the second half fiscal 2022 Executive Officer Bonus Plan (the “Second Half Bonus Plan”), based on the Company’s achievement of revenue and Adjusted EBITDA financial goals for such period. In addition, Adjusted EBITDA may |
|
| May 5, 2022 |
Exhibit 10.3 SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT This Second Amendment to Loan and Security Agreement (this “Amendment”) is entered into this 29th day of March, 2022, by and between SILICON VALLEY BANK, a California corporation (“Bank”) and CARDIOVASCULAR SYSTEMS, INC., a Delaware corporation (“Borrower”). Recitals A. Bank and Borrower have entered into that certain Loan and Security A |
|
| May 5, 2022 |
Separation Agreement, dated March 3, 2022, by and between the Company and Ryan Egeland. Exhibit 10.2 February 28, 2022 (Revised per your request and delivered via email on March 2, 2022) Via Email Personal and Confidential Ryan Egeland [ADDRESS REDACTED] Re: Separation Agreement and Release Dear Ryan: As you know, your employment with Cardiovascular Systems, Inc. (“CSI”) will end effective at the close of business on March 3, 2022 (the “Separation Date). The purpose of this Separatio |
|
| May 4, 2022 |
Exhibit 99.1 CARDIOVASCULAR SYSTEMS, INC. REPORTS FISCAL 2022 THIRD QUARTER FINANCIAL RESULTS Conference Call Scheduled for Today, May 4, 2022, at 8:00 a.m. CT (9:00 a.m. ET) ?Revenues of $56.2 million decreased 4.9% sequentially compared to second quarter this year and decreased 11.1% compared to third quarter last year ?Fiscal year 22 revenue guidance narrowed to $235 million to $240 million ?An |
|
| May 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2022 CARDIOVASCULAR SYSTEMS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 000-52082 41-1698056 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| May 4, 2022 |
csiiq3earningssupplement ©2022 Cardiovascular Systems, Inc. All Rights Reserved. Q3 FY22 Earnings Supplement May 4, 2022 Safe Harbor This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Report Act of 1995, which are provided under the protection of the safe harbor for forward-looking statements provided by that Act. For example, statements i |
|
| April 22, 2022 |
CARDIOVASCULAR SYSTEMS, INC. 1225 Old Highway 8 Northwest Saint Paul, MN 55112 (651) 259-1600 CARDIOVASCULAR SYSTEMS, INC. 1225 Old Highway 8 Northwest Saint Paul, MN 55112 (651) 259-1600 April 22, 2022 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, DC 20549 Attn: Michael Fay Brian Cascio RE: Cardiovascular Systems, Inc. Form 10-K for the fiscal year ended June 30, 2021 Filed Augus |
|
| March 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2022 CARDIOVASCULAR SYSTEMS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 000-52082 41-1698056 (State or Other Jurisdiction of Incorporation) (Commis |
|
| March 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2022 CARDIOVASCULAR SYSTEMS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 000-52082 41-1698056 (State or Other Jurisdiction of Incorporation) (Com |
|
| February 17, 2022 |
CARDIOVASCULAR SYSTEMS, INC. 1225 Old Highway 8 Northwest Saint Paul, MN 55112 (651) 259-1600 Confidential Treatment Requested By Cardiovascular Systems, Inc. CERTAIN PORTIONS OF THIS LETTER, MARKED WITH [***], HAVE BEEN OMITTED AND FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT UNDER SECURITIES AND EXCHANGE COMMISSION RULE 83 (17 C.F.R. ? 200.83). CARDIOVASCULAR SYSTEMS, INC. 1225 Old Highway 8 Northwest Saint Paul, MN 55112 |
|
| February 14, 2022 |
CSII / Cardiovascular Systems Inc / BROWN CAPITAL MANAGEMENT LLC Passive Investment SC 13G/A 1 fp0072379sc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 8)* Cardiovascular Systems, Inc. (Name of Issuer) Common Stock, $0.001 Par Value Per Share (Title of Class of Securities) 14161 |
|
| February 9, 2022 |
CSII / Cardiovascular Systems Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Cardiovascular Systems Inc. Title of Class of Securities: Common Stock CUSIP Number: 141619106 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| February 3, 2022 |
?2022 Cardiovascular Systems, Inc. All Rights Reserved. Q2 FY22 Earnings Supplement February 3, 2022 Safe Harbor This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Report Act of 1995, which are provided under the protection of the safe harbor for forward-looking statements provided by that Act. For example, statements in this presentation |
|
| February 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 3, 2022 CARDIOVASCULAR SYSTEMS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 000-52082 41-1698056 (State or Other Jurisdiction of Incorporation) (Comm |
|
| February 3, 2022 |
Transition Agreement, dated December 16, 2021, by and between the Company and David Whitescarver. Exhibit 10.2 Via Email To: David Whitescarver, Vice President, Corporate Development & Intellectual Property Cc: Steve Rempe, Chief Human Resources Officer Re: Transition Agreement Dear David: As you know, you have indicated to Cardiovascular Systems, Inc. (?CSI?) that you plan to voluntarily resign your employment with CSI for the purpose of retirement. The purpose of this letter agreement is to |
|
| February 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 00 |
|
| February 3, 2022 |
Exhibit 99.1 CARDIOVASCULAR SYSTEMS, INC. REPORTS FISCAL 2022 SECOND QUARTER FINANCIAL RESULTS Conference Call Scheduled for Today, February 3, 2022, at 8:00 a.m. CT (9:00 a.m. ET) ?Revenues of $59.1 million increased 1.3% sequentially compared to first quarter this year and decreased 7.8% compared to second quarter last year ?Procedure volumes adversely impacted by hospital constraints and staffi |
|
| November 24, 2021 |
CARDIOVASCULAR SYSTEMS, INC. INITIATES VOLUNTARY RECALL OF WIRION® EMBOLIC PROTECTION SYSTEM Exhibit 99.1 CARDIOVASCULAR SYSTEMS, INC. INITIATES VOLUNTARY RECALL OF WIRION? EMBOLIC PROTECTION SYSTEM St. Paul, Minn. ? November 24, 2021 ? Cardiovascular Systems, Inc. (CSI?) (NASDAQ: CSII) has initiated a voluntary recall of unused WIRION Embolic Protection Systems (WIRION) due to complaints of filter breakage during retrieval. CSI has informed all affected healthcare facilities to discontin |
|
| November 24, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 24, 2021 CARDIOVASCULAR SYSTEMS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 000-52082 41-1698056 (State or Other Jurisdiction of Incorporation) (Com |
|
| November 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under the Securities Act of 1933 CARDIOVASCULAR SYSTEMS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 41-1698056 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification Number) 1225 Old Highway 8 Northwest St. Paul, Minnesota 55112-6 |
|
| November 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 11, 2021 CARDIOVASCULAR SYSTEMS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 000-52082 41-1698056 (State or Other Jurisdiction of Incorporation) (Com |
|
| November 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0 |
|
| November 9, 2021 |
Exhibit 99.1 CARDIOVASCULAR SYSTEMS, INC. REPORTS FISCAL 2022 FIRST QUARTER FINANCIAL RESULTS Conference Call Scheduled for Today, November 9, 2021, at 8:00 AM CT (9:00 AM ET) ?Revenues of $58.4 million decreased 3.6% compared to first quarter last year ?Procedure volumes adversely impacted by hospital constraints and staffing shortages caused by the COVID-19 Delta variant ?Management provides upd |
|
| November 9, 2021 |
?2021 Cardiovascular Systems, Inc. All Rights Reserved. Q1 FY22 Earnings Supplement November 9, 2021 Safe Harbor This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Report Act of 1995, which are provided under the protection of the safe harbor for forward-looking statements provided by that Act. For example, statements in this presentation |
|
| November 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2021 CARDIOVASCULAR SYSTEMS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 000-52082 41-1698056 (State or Other Jurisdiction of Incorporation) (Comm |
|
| September 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| September 29, 2021 |
DEF 14A 1 def14a-2021.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant þ Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as perm |
|
| September 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 22, 2021 CARDIOVASCULAR SYSTEMS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 000-52082 41-1698056 (State or Other Jurisdiction of Incorporation) (Co |
|
| August 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2021 CARDIOVASCULAR SYSTEMS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 000-52082 41-1698056 (State or Other Jurisdiction of Incorporation) (Commi |
|
| August 19, 2021 |
Director Compensation Arrangements. Exhibit 10.3 FISCAL 2022 DIRECTOR COMPENSATION ARRANGEMENTS For the 12 month period ending June 30, 2022, each non-employee director of Cardiovascular Systems, Inc. will receive the following compensation: ? Retainers of $45,000 for service as a Board member; $22,000 for service as the chair of the Audit committee; $20,000 for service as a chair of a Board committee other than the Audit committee; |
|
| August 19, 2021 |
Fiscal 2022 Executive Officer Bonus Plan and Equity Compensation. Exhibit 10.2 FISCAL 2022 EXECUTIVE OFFICER BONUS PLAN AND EQUITY COMPENSATION Bonus Plan For the 12-month period ending June 30, 2022, each executive officer is eligible to receive cash incentive compensation pursuant to the Fiscal 2022 Executive Officer Bonus Plan (the ?Bonus Plan?), based on the Company?s achievement of revenue and adjusted EBITDA financial goals for such period. Adjusted EBITDA |
|
| August 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-52082 CARDIOVASCULAR SYSTEMS, INC. (Exact name of registrant as speci |
|
| August 4, 2021 |
CARDIOVASCULAR SYSTEMS, INC. REPORTS FISCAL 2021 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS Exhibit 99.1 CARDIOVASCULAR SYSTEMS, INC. REPORTS FISCAL 2021 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS Conference Call Scheduled for Today, August 4, 2021, at 3:30 PM CT (4:30 PM ET) ?Revenues of $71.0 million increased 66.8% compared to fourth quarter last year and increased 12.2% sequentially compared to third quarter this year ?Fiscal 2021 revenues increased 9.5% to a record high $259 mil |
|
| August 4, 2021 |
?2021 Cardiovascular Systems, Inc. All Rights Reserved. Q4 FY21 Earnings Supplement August 4, 2021 Safe Harbor This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Report Act of 1995, which are provided under the protection of the safe harbor for forward-looking statements provided by that Act. For example, statements in this presentation re |
|
| August 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2021 CARDIOVASCULAR SYSTEMS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 000-52082 41-1698056 (State or Other Jurisdiction of Incorporation) (Commis |
|
| July 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 2021 CARDIOVASCULAR SYSTEMS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 000-52082 41-1698056 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| May 25, 2021 |
SD 1 formsdcover-2020.htm SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM SD SPECIALIZED DISCLOSURE REPORT CARDIOVASCULAR SYSTEMS, INC. (Exact name of registrant as specified in its charter) Commission File No. 000-52082 Delaware No. 41-1698056 (State or other jurisdiction of (IRS Employer incorporation or organization) Identification No.) 1225 Old Highway 8 Northwest |
|
| May 25, 2021 |
EX-1.01 2 ex101conflictmineralsrepor.htm EX-1.01 Exhibit 1.01 CONFLICT MINERALS REPORT For the reporting period from January 1, 2020 to December 31, 2020 Cardiovascular Systems, Inc. Cardiovascular Systems, Inc. (the “Company,” “we,” “us,” “our,” or “CSI®”), based in St. Paul, Minnesota, is a medical device company focused on developing and commercializing innovative solutions for treating vascula |
|
| May 6, 2021 |
CARDIOVASCULAR SYSTEMS, INC. REPORTS FISCAL 2021 THIRD-QUARTER FINANCIAL RESULTS Exhibit 99.1 CARDIOVASCULAR SYSTEMS, INC. REPORTS FISCAL 2021 THIRD-QUARTER FINANCIAL RESULTS Conference Call Scheduled for Today, May 6, 2021, at 3:30 PM CT (4:30 PM ET) ?Revenues of $63.3 million increased 3.4% compared to third quarter last year ?Net loss of $6.0 million includes $3.4 million related to acquisition of peripheral support catheters from WavePoint Medical, LLC ?Management provides |
|
| May 6, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2021 CARDIOVASCULAR SYSTEMS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 000-52082 41-1698056 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| May 6, 2021 |
?2021 Cardiovascular Systems, Inc. All Rights Reserved. Q3 FY21 Earnings Supplement May 6, 2021 Safe Harbor This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Report Act of 1995, which are provided under the protection of the safe harbor for forward-looking statements provided by that Act. For example, statements in this presentation regar |
|
| May 6, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-5 |
|
| April 8, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2021 CARDIOVASCULAR SYSTEMS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 000-52082 41-1698056 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| April 8, 2021 |
Exhibit 99.1 CARDIOVASCULAR SYSTEMS, INC. ANNOUNCES INVESTMENT AND ACQUISITION OPTION AGREEMENT WITH TELEHEALTH COMPANY, CAREPICS, LLC St. Paul, Minn. ? April 8, 2021 ? Cardiovascular Systems, Inc. (CSI?) (NASDAQ: CSII) announced today that it has completed a minority investment and entered into an acquisition option agreement with CarePICS, LLC (CarePICS?), a telehealth company offering a virtual |
|
| March 22, 2021 |
Exhibit 99.1 CARDIOVASCULAR SYSTEMS, INC. ANNOUNCES ACQUISITION OF PERIPHERAL SUPPORT CATHETERS FROM WAVEPOINT MEDICAL, LLC Agreement also includes development of portfolio of CTO products St. Paul, Minn. ? March 22, 2021 ? Cardiovascular Systems, Inc. (CSI?) (NASDAQ: CSII) announced today that it has acquired a line of peripheral support catheters from WavePoint Medical, LLC. Peripheral support c |
|
| March 22, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2021 CARDIOVASCULAR SYSTEMS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 000-52082 41-1698056 (State or Other Jurisdiction of Incorporation) (Commis |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 7)* Cardiovascular Systems, Inc. (Name of Issuer) Common Stock, $0.001 Par Value Per Share (Title of Class of Securities) 141619106 (CUSIP Number) Eddie C. Br |
|
| February 10, 2021 |
SC 13G/A 1 tv0462-cardiovascularsystems.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Cardiovascular Systems Inc. Title of Class of Securities: Common Stock CUSIP Number: 141619106 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate bo |
|
| February 4, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 00 |
|
| February 4, 2021 |
Exhibit 10.1 FOURTH AMENDMENT TO BUILD-TO-SUIT LEASE This Fourth Amendment to Build-To-Suit Lease Agreement (this “Fourth Amendment”) by and between the Pearland Economic Development Corporation, a corporation operating under Chapter 505 of the Texas Local Government Code (“Landlord”) and Cardiovascular Systems, Inc., a Delaware corporation (“Tenant”), is effective as of the date of the last signa |
|
| February 3, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 3, 2021 CARDIOVASCULAR SYSTEMS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 000-52082 41-1698056 (State or Other Jurisdiction of Incorporation) (Comm |
|
| February 3, 2021 |
EX-99.2 3 csiiq2earningsslides-2x3.htm EX-99.2 ©2020 Cardiovascular Systems, Inc. All Rights Reserved. Q2 FY21 Earnings Supplement February 3, 2021 Safe Harbor This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Report Act of 1995, which are provided under the protection of the safe harbor for forward-looking statements provided by that Act |
|
| February 3, 2021 |
Exhibit 99.1 CARDIOVASCULAR SYSTEMS, INC. REPORTS FISCAL 2021 SECOND-QUARTER FINANCIAL RESULTS Conference Call Scheduled for Today, February 3, 2021, at 3:30 PM CT (4:30 PM ET) •Revenues of $64.2 million increased 6% sequentially compared to first quarter •Net loss was $0.1 million, or $0.00 per basic and diluted share •Management provides fiscal 2021 third quarter revenue guidance of $60 million |
|
| February 1, 2021 |
Exhibit 99.1 CARDIOVASCULAR SYSTEMS, INC. ANNOUNCES PARTNERSHIP WITH CHANSU VASCULAR TECHOLOGIES, LLC TO DEVELOP NEW DRUG-COATED BALLOON TECHNOLOGY St. Paul, Minn. – February 1, 2021 – Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII) announced today that it has partnered with Chansu Vascular Technologies, LLC (CVT) to develop novel peripheral and coronary everolimus drug-coated balloons (DCBs). |
|
| February 1, 2021 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 1, 2021 CARDIOVASCULAR SYSTEMS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 000-52082 41-1698056 (State or Other Jurisdiction of Incorporation) (Comm |
|
| January 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 27, 2021 CARDIOVASCULAR SYSTEMS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 000-52082 41-1698056 (State or Other Jurisdiction of Incorporation) (Comm |
|
| January 27, 2021 |
CARDIOVASCULAR SYSTEMS, INC. ANNOUNCES SACHIN H. JAIN, MD, MBA, JOINS BOARD OF DIRECTORS EX-99.1 2 a991jain.htm EX-99.1 Exhibit 99.1 CARDIOVASCULAR SYSTEMS, INC. ANNOUNCES SACHIN H. JAIN, MD, MBA, JOINS BOARD OF DIRECTORS St. Paul, Minn., January 27, 2021 – Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced the a |
|
| December 22, 2020 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2020 CARDIOVASCULAR SYSTEMS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 000-52082 41-1698056 (State or Other Jurisdiction of Incorporation) (Com |
|
| November 12, 2020 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 11, 2020 CARDIOVASCULAR SYSTEMS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 000-52082 41-1698056 (State or Other Jurisdiction of Incorporation) (Com |
|
| November 5, 2020 |
EX-10.2 3 csi-amendmentno1toprod.htm EX-10.2 Exhibit 10.2 *Certain information where indicated below in brackets has been excluded from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed* AMENDMENT NO. 1 TO PRODUCT SCHEDULE This Amendment is made effective as of the last date indicated on the signature page hereto, by and between Cardiova |
|
| November 5, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0 |
|
| November 5, 2020 |
Exhibit 10.3 *Certain information where indicated below in brackets has been excluded from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed* Amendment to Purchasing Agreement Agreement No.: HPG-4037 Vendor: Cardiovascular Systems, Inc. Agreement Date: May 1, 2018 Amendment Date: October 1, 2020 Effective as of the Amendment Date above, |
|
| November 5, 2020 |
upply Agreement, between Cardiovascular Systems, Inc. and Fresenius Kabi AB Exhibit 10.1 *Certain information where indicated below in brackets has been excluded from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed* SUPPLY AGREEMENT This Supply Agreement (the “Agreement”) is effective as of the 4th day of April, 2011 (the “Effective Date”) by and between (1) Fresenius Kabi AB, Rapsgatan 7, 75324 Uppsala, Swede |
|
| November 4, 2020 |
Exhibit 99.1 CARDIOVASCULAR SYSTEMS, INC. REPORTS FISCAL 2021 FIRST-QUARTER FINANCIAL RESULTS Conference Call Scheduled for Today, November 4, 2020, at 3:30 PM CT (4:30 PM ET) •Revenues of $60.5 million increased 42% sequentially and decreased 6.1% compared to last year •Net loss was $2.1 million, or $0.05 per basic and diluted share •Management provides fiscal 2021 second quarter revenue guidance |
|
| November 4, 2020 |
EX-99.2 3 csiiq1earningsslides11-4.htm EX-99.2 Q1 FY21 Earnings Call November 4, 2020 Safe Harbor FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Report Act of 1995, which are provided under the protection of the safe harbor for forward-looking statements provided by that Act. For example, statements in this p |
|
| November 4, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2020 CARDIOVASCULAR SYSTEMS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 000-52082 41-1698056 (State or Other Jurisdiction of Incorporation) (Comm |
|
| September 29, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant þ Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) þ Defin |
|
| September 29, 2020 |
DEFA14A 1 defa14a-2020.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant þ Filed by a Party other than the Registrant ¨ Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as per |
|
| August 20, 2020 |
Fiscal 2021 Executive Officer Bonus Plan and Equity Compensation. EX-10.2 2 ex102-fy21execincentiv.htm EX-10.2 Exhibit 10.2 FISCAL 2021 EXECUTIVE OFFICER BONUS PLAN AND EQUITY COMPENSATION Bonus Plan For the 12-month period ending June 30, 2021, each executive officer is eligible to receive cash incentive compensation pursuant to the Fiscal 2021 Executive Officer Bonus Plan (the “Bonus Plan”), based on the Company’s achievement of revenue and Adjusted EBITDA fin |
|
| August 20, 2020 |
Exhibit 10.47 *Certain information where indicated below in brackets has been excluded from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed* June 18, 2020 Loyal M. Peterman, Jr. Abrasive Technology, Inc. 8400 Green Meadows Dr. P.O. Box 545 Lewis Center, OH 43035 Dear Butch: This letter agreement confirms the terms and conditions on whi |
|
| August 20, 2020 |
CARDIOVASCULAR SYSTEMS, INC. ANNOUNCES KELVIN WOMACK JOINS BOARD OF DIRECTORS EX-99.1 2 a991womack.htm EX-99.1 Exhibit 99.1 CARDIOVASCULAR SYSTEMS, INC. ANNOUNCES KELVIN WOMACK JOINS BOARD OF DIRECTORS St. Paul, Minn., August 20, 2020 – Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced the addition of |
|
| August 20, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-52082 CARDIOVASCULAR SYSTEMS, INC. (Exact name of registrant as speci |
|
| August 20, 2020 |
Fiscal 2021 Director Compensation Arrangements. Exhibit 10.3 FISCAL 2021 DIRECTOR COMPENSATION ARRANGEMENTS For the 12 month period ending June 30, 2021, each non-employee director of Cardiovascular Systems, Inc. will receive the following compensation: ● Retainers of $45,000 for service as a Board member; $22,000 for service as the chair of the Audit committee; $20,000 for service as a chair of a Board committee other than the Audit committee; |
|
| August 20, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 20, 2020 CARDIOVASCULAR SYSTEMS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 000-52082 41-1698056 (State or Other Jurisdiction of Incorporation) (Commi |
|
| August 4, 2020 |
EX-99.2 3 csiiq4slides8-4x20final.htm EX-99.2 Q4 FY20 Earnings Call August 4, 2020 Safe Harbor FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Report Act of 1995, which are provided under the protection of the safe harbor for forward-looking statements provided by that Act. For example, statements in this pres |
|
| August 4, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2020 CARDIOVASCULAR SYSTEMS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 000-52082 41-1698056 (State or Other Jurisdiction of Incorporation) (Commis |
|
| August 4, 2020 |
Exhibit 99.1 CARDIOVASCULAR SYSTEMS, INC. REPORTS FISCAL 2020 FOURTH-QUARTER FINANCIAL RESULTS Conference Call Scheduled for Today, August 4, 2020, at 3:30 PM CT (4:30 PM ET) •Revenues of $42.5 million decreased 37.6% from fourth quarter last year •Net loss was $15.2 million, or $0.43 per basic and diluted share •Fiscal year 2020 revenues declined 4.6% to $236.5 million •Equity issuance raised $13 |
|
| July 29, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23, 2020 CARDIOVASCULAR SYSTEMS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 000-52082 41-1698056 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| June 23, 2020 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 19, 2020 CARDIOVASCULAR SYSTEMS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 000-52082 41-1698056 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| June 18, 2020 |
CARDIOVASCULAR SYSTEMS ANNOUNCES EXERCISE OF UNDERWRITERS’ OPTION EX-99.1 2 a991csiioptionrelease.htm EX-99.1 Exhibit 99.1 CARDIOVASCULAR SYSTEMS ANNOUNCES EXERCISE OF UNDERWRITERS’ OPTION St. Paul, Minn. – June 18, 2020 – Cardiovascular Systems, Inc. (CSI) (Nasdaq: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced that the underwrit |
|
| June 18, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2020 CARDIOVASCULAR SYSTEMS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 000-52082 41-1698056 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| June 12, 2020 |
Underwriting Agreement, dated June 9, 2020 EX-1.1 2 charger-underwritingag.htm EX-1.1 Exhibit 1.1 3,676,471 Shares Cardiovascular Systems, Inc. Common Stock UNDERWRITING AGREEMENT June 9, 2020 Barclays Capital Inc. SVB Leerink LLC, As Representatives of the several Underwriters named in Schedule I attached hereto c/o Barclays Capital Inc. 745 Seventh Avenue New York, New York 10019 c/o SVB Leerink LLC 1301 Avenue of the Americas, 12th Floo |
|
| June 12, 2020 |
CARDIOVASCULAR SYSTEMS PRICES PUBLIC OFFERING OF COMMON STOCK Exhibit 99.2 CARDIOVASCULAR SYSTEMS PRICES PUBLIC OFFERING OF COMMON STOCK St. Paul, Minn. – June 9, 2020 – Cardiovascular Systems, Inc. (CSI) (Nasdaq: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced the pricing of its previously announced underwritten public offerin |
|
| June 12, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2020 CARDIOVASCULAR SYSTEMS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 000-52082 41-1698056 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| June 12, 2020 |
CARDIOVASCULAR SYSTEMS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK EX-99.1 4 a991launchrelease.htm EX-99.1 Exhibit 99.1 CARDIOVASCULAR SYSTEMS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK St. Paul, Minn. – June 9, 2020 – Cardiovascular Systems, Inc. (CSI) (Nasdaq: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced that it has com |
|
| June 11, 2020 |
3,676,471 Shares Cardiovascular Systems, Inc. Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-228686 PROSPECTUS SUPPLEMENT (To Prospectus dated December 6, 2018) 3,676,471 Shares Cardiovascular Systems, Inc. Common Stock We are offering 3,676,471 shares of our common stock. Our common stock trades on The Nasdaq Global Select Market under the symbol “CSII.” On June 8, 2020, the last reported sale price of our comm |
|
| June 9, 2020 |
Subject to Completion, dated June 9, 2020 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-228686 The information in this preliminary prospectus is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus is not an offer to sell these securities and we are not soliciting offers |
|
| May 27, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM SD SPECIALIZED DISCLOSURE REPORT CARDIOVASCULAR SYSTEMS, INC. |
|
| May 27, 2020 |
EX-1.01 2 ex101conflictmineralsreport.htm EX-1.01 Exhibit 1.01 CONFLICT MINERALS REPORT For the reporting period from January 1, 2019 to December 31, 2019 Cardiovascular Systems, Inc. Cardiovascular Systems, Inc. (the “Company,” “we,” “us,” “our,” or “CSI®”), based in St. Paul, Minnesota, is a medical device company focused on developing and commercializing innovative solutions for treating vascul |
|
| May 7, 2020 |
Exhibit 10.4 RESTRICTED STOCK UNIT AGREEMENT CARDIOVASCULAR SYSTEMS, INC. 2017 EQUITY INCENTIVE PLAN THIS AGREEMENT, made effective as of , 20 by and between CARDIOVASCULAR SYSTEMS, INC., a Delaware corporation (the “Company”), and (“Participant”). W I T N E S S E T H: WHEREAS, Participant on the date hereof is a nonemployee director of the Company or one of its Subsidiaries; and WHEREAS, the Comp |
|
| May 7, 2020 |
Exhibit 10.2 RESTRICTED STOCK AGREEMENT CARDIOVASCULAR SYSTEMS, INC. 2017 EQUITY INCENTIVE PLAN THIS AGREEMENT is made effective as of , 20, by and between CARDIOVASCULAR SYSTEMS, INC., a Delaware corporation (the “Company”), and (the “Participant”). W I T N E S S E T H: WHEREAS, the Participant is, on the date hereof, a key employee, officer, director of, or a consultant or advisor to, the Compan |
|
| May 7, 2020 |
Exhibit 10.3 RESTRICTED STOCK UNIT AGREEMENT CARDIOVASCULAR SYSTEMS, INC. 2017 EQUITY INCENTIVE PLAN THIS AGREEMENT, made effective as of , 20 by and between CARDIOVASCULAR SYSTEMS, INC., a Delaware corporation (the “Company”), and (“Participant”). W I T N E S S E T H: WHEREAS, Participant on the date hereof is a nonemployee director of the Company or one of its Subsidiaries; and WHEREAS, the Comp |
|
| May 7, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-5 |
|
| May 7, 2020 |
Exhibit 10.10 *Certain information where indicated below in brackets has been excluded from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed* AMENDMENT NO. 2 TO PRODUCT SCHEDULE This Amendment is made effective as of the last date indicated on the signature page hereto, by and between Cardiovascular Systems, Inc. (“CSI”) and Fresenius K |
|
| May 7, 2020 |
Exhibit 10.1 AMENDED AND RESTATED CARDIOVASCULAR SYSTEMS, INC. 2017 EQUITY INCENTIVE PLAN Amended as of March 12, 2020 SECTION 1. DEFINITIONS As used herein, the following terms shall have the meanings indicated below: (a)“Administrator” shall mean the Board of Directors of the Company, or one or more Committees appointed by the Board of Directors, as the case may be. (b)“Affiliate(s)” shall mean |
|
| May 7, 2020 |
Exhibit 10.9 AMENDMENT NO. 2 TO SUPPLY AGREEMENT This Amendment is made effective as of the last date indicated on the signature page hereto, by and between Cardiovascular Systems, Inc. (“CSI”) and Fresenius Kabi AB (“FRESENIUS”). WHEREAS, CSI and FRESENIUS entered into a Supply Agreement dated as of April 4, 2011 (the “Agreement”); WHEREAS, CSI and FRESENIUS entered into an Amendment No. 1 to Sup |
|
| May 7, 2020 |
EX-10.5 6 a105formofperformance-.htm EX-10.5 Exhibit 10.5 RESTRICTED STOCK AGREEMENT PERFORMANCE-BASED VESTING CARDIOVASCULAR SYSTEMS, INC. 2017 EQUITY INCENTIVE PLAN CARDIOVASCULAR SYSTEMS, INC., a Delaware corporation (the “Company”) has engaged Morgan Stanley Smith Barney LLC (“MSSB”) to maintain an online system to provide secure account access to participants receiving grants (each, a “Partic |
|
| May 7, 2020 |
Exhibit 10.8 FIRST Amendment to Loan and security agreement This First Amendment to Loan and Security Agreement (this “Amendment”) is entered into this 26th day of March, 2020, by and between Silicon Valley Bank (“Bank”) and CARDIOVASCULAR SYSTEMS, INC., a Delaware corporation (“Borrower”). Recitals A. Bank and Borrower have entered into that certain Loan and Security Agreement dated as of March 3 |
|
| May 7, 2020 |
EX-10.7 8 a107formofstockoptiona.htm EX-10.7 Exhibit 10.7 [INCENTIVE][NONQUALIFIED] STOCK OPTION AGREEMENT CARDIOVASCULAR SYSTEMS, INC. AMENDED AND RESTATED 2017 EQUITY INCENTIVE PLAN CARDIOVASCULAR SYSTEMS, INC., a Delaware corporation (the “Company”), has engaged Morgan Stanley Smith Barney LLC (“MSSB”) to maintain an online system to provide secure account access to participants receiving grant |
|
| May 7, 2020 |
Exhibit 10.6 RESTRICTED STOCK AGREEMENT TIME-BASED VESTING CARDIOVASCULAR SYSTEMS, INC. 2017 EQUITY INCENTIVE PLAN CARDIOVASCULAR SYSTEMS, INC., a Delaware corporation (the “Company”) has engaged Morgan Stanley Smith Barney LLC (“MSSB”) to maintain an online system to provide secure account access to participants receiving grants (each, a “Participant”) under the Company’s 2017 Equity Incentive Pl |
|
| May 5, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2020 CARDIOVASCULAR SYSTEMS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 000-52082 41-1698056 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| May 5, 2020 |
csiq3earningsslides5-5x2 Q3 FY20 Earnings Call May 5, 2020 Safe Harbor FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Report Act of 1995, which are provided under the protection of the safe harbor for forward-looking statements provided by that Act. |
|
| May 5, 2020 |
Exhibit 99.1 CARDIOVASCULAR SYSTEMS, INC. REPORTS FISCAL 2020 THIRD-QUARTER FINANCIAL RESULTS Conference Call Scheduled for Today, May 5, 2020, at 3:30 PM CT (4:30 PM ET) •Healthcare system response to COVID-19 pandemic delayed atherectomy procedures and negatively impacted third quarter results •Revenues of $61.2 million decreased 3.4% from third quarter last year •Net loss was $2.9 million, or $ |
|
| April 1, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2020 CARDIOVASCULAR SYSTEMS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 000-52082 41-1698056 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| March 26, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2020 CARDIOVASCULAR SYSTEMS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 000-52082 41-1698056 (State or Other Jurisdiction of Incorporation) (Commis |
|
| March 20, 2020 |
Regulation FD Disclosure, Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2020 CARDIOVASCULAR SYSTEMS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 000-52082 41-1698056 (State or Other Jurisdiction of Incorporation) (Commis |
|
| February 14, 2020 |
CSII / Cardiovascular Systems, Inc. / BROWN CAPITAL MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 6)* Cardiovascular Systems, Inc. (Name of Issuer) Common Stock, $0.001 Par Value Per Share (Title of Class of Securities) 141619106 (CUSIP Number) Eddie C. Br |
|
| February 11, 2020 |
CSII / Cardiovascular Systems, Inc. / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Cardiovascular Systems Inc Title of Class of Securities: Common Stock CUSIP Number: 141619106 Date of Event Which Requires Filing of this Statement: December 31, 2019 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b |
|
| February 6, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 00 |
|
| February 5, 2020 |
EX-99.1 2 exhibit991-02052020.htm EX-99.1 Exhibit 99.1 CARDIOVASCULAR SYSTEMS, INC. REPORTS FISCAL 2020 SECOND-QUARTER FINANCIAL RESULTS Conference Call Scheduled for Today, February 5, 2020, at 3:30 PM CT (4:30 PM ET) •Revenues of $68.3 million increased 13.5% from second quarter last year •Net loss was $3.4 million, or $0.10 per basic and diluted share •Company raises low end of fiscal 2020 reve |
|
| February 5, 2020 |
csiq2earningsslides2-5x2 Q2 FY20 Earnings Call February 5, 2020 Safe Harbor FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Report Act of 1995, which are provided under the protection of the safe harbor for forward-looking statements provided by that Act. |
|
| February 5, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 5, 2020 CARDIOVASCULAR SYSTEMS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 000-52082 41-1698056 (State or Other Jurisdiction of Incorporation) (Comm |
|
| January 28, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4 )* Cardiovascular Systems Inc (Name of Issuer) Common Stock (Title of Class of Securities) 141619106 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| November 14, 2019 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2019 CARDIOVASCULAR SYSTEMS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 000-52082 41-1698056 (State or Other Jurisdiction of Incorporation) (Com |
|
| November 12, 2019 |
EX-99.1 2 ex991111219.htm EXHIBIT 99.1 Exhibit 99.1 CARDIOVASCULAR SYSTEMS, INC. ANNOUNCES STEPHEN STENBECK JOINS BOARD OF DIRECTORS Brent Blackey Retires after 12 Years of Service St. Paul, Minn., November 12, 2019 – Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral a |
|
| November 12, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2019 CARDIOVASCULAR SYSTEMS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 000-52082 41-1698056 (State or Other Jurisdiction of Incorporation) (Com |
|
| October 31, 2019 |
, 2019, by and between the Company and Laura J. Gillund. EX-10.1 2 lgseparationagreement.htm EX-10.1 Exhibit 10.1 August 30, 2019 Via Email Personal and Confidential [Address Redacted] Re: Separation Agreement and Release Dear Laura: As you know, your retirement will be effective and your employment with Cardiovascular Systems, Inc. (“CSI”) will end effective at the close of business on August 30, 2019 (the “Separation Date”), due to your voluntary resi |
|
| October 31, 2019 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0 |
|
| October 31, 2019 |
Consulting Agreement dated August 31, 2019, by and between the Company and Laura J. Gillund. EX-10.2 3 lgconsultingagreement.htm EX-10.2 Exhibit 10.2 CONSULTING AGREEMENT EFFECTIVE DATE: August 31, 2019 PARTIES: Cardiovascular Systems, Inc. (“CSI”) 1225 Old Highway 8 NW St. Paul, MN 55112 Laura Gillund (“Consultant”) [Address Redacted] RECITAL: CSI and Consultant desire to enter into an arrangement by which Consultant will provide consulting services to CSI pursuant to the terms and condi |
|
| October 30, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2019 CARDIOVASCULAR SYSTEMS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 000-52082 41-1698056 (State or Other Jurisdiction of Incorporation) (Comm |
|
| October 30, 2019 |
EX-99.1 2 exhibit991-10292019.htm EX-99.1 Exhibit 99.1 CARDIOVASCULAR SYSTEMS, INC. REPORTS FISCAL 2020 FIRST-QUARTER FINANCIAL RESULTS Conference Call Scheduled for Today, October 29, 2019, at 3:30 PM CT (4:30 PM ET) •Revenues of $64.5 million increased 14.6% from first quarter last year •Net loss was $5.8 million, or $0.17 per basic and diluted share •Management reiterates fiscal 2020 financial |
|
| October 30, 2019 |
csiiq1fy20earningsslides Q1 FY20 Earnings Call October 29, 2019 Safe Harbor FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Report Act of 1995, which are provided under the protection of the safe harbor for forward-looking statements provided by that Act. |
|
| October 1, 2019 |
CSII / Cardiovascular Systems, Inc. DEFA14A - - DEFA14A DEFA14A 1 defa14a-2019.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant þ Filed by a Party other than the Registrant ¨ Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as per |
|
| October 1, 2019 |
Proxy Statement on Schedule 14A DEF 14A 1 def14a-2019.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant þ Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as perm |
|
| September 26, 2019 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 26, 2019 CARDIOVASCULAR SYSTEMS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 000-52082 41-1698056 (State or Other Jurisdiction of Incorporation) (Co |
|
| September 26, 2019 |
EX-99.1 2 tctfinal926.htm EX-99.1 Cardiovascular Systems, Inc. Product Pipeline Update September 26, 2019 ©2019 Cardiovascular Systems, Inc. All Rights Reserved. Safe Harbor This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Report Act of 1995, which are provided under the protection of the safe harbor for forward-looking statements provid |
|
| September 9, 2019 |
CSII / Cardiovascular Systems, Inc. / BROWN CAPITAL MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 5)* Cardiovascular Systems, Inc. (Name of Issuer) Common Stock, $0.001 Par Value Per Share (Title of Class of Securities) 141619106 (CUSIP Number) Eddie C. Br |
|
| September 4, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 30, 2019 Cardiovascular Systems, Inc. (Exact name of Registrant as Specified in its Charter) Delaware 000-52082 41-1698056 (State or Other Jurisdiction of Incorporation) (Commi |
|
| August 23, 2019 |
Fiscal Year 2020 Director Compensation Arrangements. Exhibit 10.3 FISCAL 2020 DIRECTOR COMPENSATION ARRANGEMENTS For the 12 month period ending June 30, 2020, each non-employee director of Cardiovascular Systems, Inc. will receive the following compensation: ● Retainers of $45,000 for service as a Board member; $22,000 for service as the chair of the Audit committee; $20,000 for service as a chair of a Board committee other than the Audit committee; |
|
| August 23, 2019 |
Fiscal 2020 Executive Officer Bonus Plan and Equity Compensation. Exhibit 10.2 FISCAL 2020 EXECUTIVE OFFICER BONUS PLAN AND EQUITY COMPENSATION Bonus Plan For the 12-month period ending June 30, 2020, each executive officer of Cardiovascular Systems, Inc. (the “Company”) is eligible to receive cash incentive compensation pursuant to the Fiscal 2020 Executive Officer Bonus Plan (the “Bonus Plan”), based on the Company’s achievement of revenue and Adjusted EBITDA |
|
| August 23, 2019 |
Exhibit 4.3 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of June 30, 2019, Cardiovascular Systems, Inc. (the “Company”) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): Common Stock. Description of Common Stock The following description of the Co |
|
| August 23, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-52082 CARDIOVASCULAR SYSTEMS, INC. (Exact name of registrant as speci |
|
| August 6, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2019 Cardiovascular Systems, Inc. (Exact name of Registrant as Specified in its Charter) Delaware 000-52082 41-1698056 (State or Other Jurisdiction of Incorporation) (Commis |
|
| August 6, 2019 |
EX-99.1 2 a99186release.htm EXHIBIT 99.1 Exhibit 99.1 CARDIOVASCULAR SYSTEMS, INC. REPORTS FISCAL 2019 FOURTH-QUARTER FINANCIAL RESULTS Conference Call Scheduled for Today, August 6, 2019, at 3:30 PM CT (4:30 PM ET) • Revenues of $68.2 million increased 15.4% from fourth quarter last year • Net income was $1.5 million, or $0.04 per basic and diluted share • Company introduces fiscal 2020 financial |
|
| August 6, 2019 |
csiq4earningsslides8619 Q4 FY19 Earnings Call August 6, 2019 Safe Harbor FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Report Act of 1995, which are provided under the protection of the safe harbor for forward-looking statements provided by that Act. |
|
| August 5, 2019 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2019 Cardiovascular Systems, Inc. (Exact name of Registrant as Specified in its Charter) Delaware 000-52082 41-1698056 (State or Other Jurisdiction of Incorporation) (Commis |
|
| August 5, 2019 |
Exhibit 99.1 CARDIOVASCULAR SYSTEMS, INC. ACQUIRES GARDIA MEDICAL LTD.’S WIRION™ EMBOLIC PROTECTION SYSTEM CSI to Commercialize Product upon Successful Manufacturing Transfer St. Paul, Minn., August 5, 2019 – Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and corona |
|
| July 25, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2019 Cardiovascular Systems, Inc. (Exact name of Registrant as Specified in its Charter) Delaware 000-52082 41-1698056 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| July 25, 2019 |
CARDIOVASCULAR SYSTEMS, INC. ANNOUNCES FORMER U.S. CONGRESSMAN ERIK PAULSEN JOINS BOARD OF DIRECTORS Exhibit 99.1 CARDIOVASCULAR SYSTEMS, INC. ANNOUNCES FORMER U.S. CONGRESSMAN ERIK PAULSEN JOINS BOARD OF DIRECTORS St. Paul, Minn., July 25, 2019 – Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced the addition of independent |
|
| July 1, 2019 |
Amendment to Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2019 Cardiovascular Systems, Inc. (Exact name of Registrant as Specified in its Charter) Delaware 000-52082 41-1698056 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| May 31, 2019 |
CSII / Cardiovascular Systems, Inc. SD - - SD2018 SD 1 formsd-2018.htm SD2018 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM SD SPECIALIZED DISCLOSURE REPORT CARDIOVASCULAR SYSTEMS, INC. (Exact name of registrant as specified in its charter) Commission File No. 000-52082 Delaware No. 41-1698056 (State or other jurisdiction of (IRS Employer incorporation or organization) Identification No.) 1225 Old Highway 8 Northwest |
|
| May 31, 2019 |
Exhibit 1.01 CONFLICT MINERALS REPORT For the reporting period from January 1, 2018 to December 31, 2018 Cardiovascular Systems, Inc. Cardiovascular Systems, Inc. (the “Company,” “we,” “us,” “our,” or “CSI®”), based in St. Paul, Minnesota, is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease. The Company’s Orbital Ath |
|
| May 3, 2019 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 Commission File No. 000-52082 CARDIOVASCULAR SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware No. 41-1698056 (State or other jurisdiction |
|
| May 3, 2019 |
Transition Agreement, dated January 9, 2019, by and between the Company and Laura J. Gillund. Exhibit 10.1 Via Email To: Laura Gillund Re: Transition Agreement Dear Laura: As you know, you have indicated to Cardiovascular Systems, Inc. (“CSI”) that you plan to voluntarily resign your employment with CSI for the purpose of retirement. The purpose of this letter agreement is to confirm your and CSI’s agreement with regard to the upcoming transition and end of your employment relationship wit |
|
| May 1, 2019 |
EX-99.1 2 ex991-q319.htm EXHIBIT 99.1 Exhibit 99.1 CARDIOVASCULAR SYSTEMS, INC. REPORTS FISCAL 2019 THIRD-QUARTER FINANCIAL RESULTS Conference Call Scheduled for Today, May 1, 2019, at 3:30 PM CT (4:30 PM ET) • Revenues of $63.3 million increased 13.9% from third quarter last year • Net income was $0.7 million, or $0.02 per diluted share • Company increases fiscal 2019 revenue guidance to upper ha |
|
| May 1, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2019 Cardiovascular Systems, Inc. (Exact name of Registrant as Specified in its Charter) Delaware 000-52082 41-1698056 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| April 10, 2019 |
CSII / Cardiovascular Systems, Inc. / BROWN CAPITAL MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 4)* Cardiovascular Systems, Inc. (Name of Issuer) Common Stock, $0.001 Par Value Per Share (Title of Class of Securities) 141619106 (CUSIP Number) Eddie C. Br |
|
| February 14, 2019 |
CSII / Cardiovascular Systems, Inc. / BROWN CAPITAL MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 3)* Cardiovascular Systems, Inc. (Name of Issuer) Common Stock, $0.001 Par Value Per Share (Title of Class of Securities) 141619106 (CUSIP Number) Eddie C. Br |
|
| February 12, 2019 |
SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* Cardiovascular Systems Inc (Name of Issuer) Common Stock (Title of Class of Securities) 141619106 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate |
|
| February 11, 2019 |
CSII / Cardiovascular Systems, Inc. / VANGUARD GROUP INC Passive Investment cardiovascularsystemsinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1 )* Name of issuer: Cardiovascular Systems Inc Title of Class of Securities: Common Stock CUSIP Number: 141619106 Date of Event Which Requires Filing of this Statement: December 31, 2018 Check the |
|
| February 1, 2019 |
CSII / Cardiovascular Systems, Inc. 10-Q (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2018 Commission File No. 000-52082 CARDIOVASCULAR SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware No. 41-1698056 (State or other jurisdict |
|
| January 30, 2019 |
Exhibit 99.1 CARDIOVASCULAR SYSTEMS, INC. REPORTS FISCAL 2019 SECOND-QUARTER FINANCIAL RESULTS Conference Call Scheduled for Today, January 30, 2019, at 3:30 PM CT (4:30 PM ET) • Revenues of $60.2 million increased 14.4% from second quarter last year • Net income was $0.5 million, or $0.01 per diluted share • Company reiterates fiscal 2019 revenue guidance • Orbital atherectomy launched in Asia, E |
|
| January 30, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 a8-k013019.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2019 Cardiovascular Systems, Inc. (Exact name of Registrant as Specified in its Charter) Delaware 000-52082 41-1698056 (State or Other Jurisdictio |
|
| January 10, 2019 |
8-K 1 a8k01092019.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2019 Cardiovascular Systems, Inc. (Exact name of Registrant as Specified in its Charter) Delaware 000-52082 41-1698056 (State or Other Jurisdictio |
|
| January 7, 2019 |
EX-99.1 2 ex991release010719.htm EXHIBIT 99.1 Exhibit 99.1 CARDIOVASCULAR SYSTEMS, INC. ANNOUNCES PRELIMINARY FISCAL 2019 SECOND-QUARTER REVENUES OF $60.2 MILLION Company Narrows Fiscal 2019 Revenue Guidance to a Range of $243 million to $247 million Company to Host Second-Quarter Earnings Conference Call on January 30th St. Paul, Minn., January 7, 2019 –Cardiovascular Systems, Inc. (CSI®) (NASDAQ |
|
| January 7, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2019 Cardiovascular Systems, Inc. (Exact name of Registrant as Specified in its Charter) Delaware 000-52082 41-1698056 (State or Other Jurisdiction of Incorporation) (Commi |
|
| December 6, 2018 |
CSII / Cardiovascular Systems, Inc. S-3ASR As filed with the Securities and Exchange Commission on December 6, 2018 Registration No. |
|
| December 6, 2018 |
Form of Indenture (filed herewith) EX-4.9 2 ex49dec2018s-3.htm EXHIBIT 4.9 Exhibit 4.9 CARDIOVASCULAR SYSTEMS, INC. and , as Trustee INDENTURE Dated as of , TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS AND INCORPORATION BY REFERENCE 1 1.1. DEFINITIONS 1 1.2. OTHER DEFINITIONS 4 1.3. INCORPORATION BY REFERENCE OF TRUST INDENTURE ACT 4 1.4. RULES OF CONSTRUCTION 5 ARTICLE 2 THE SECURITIES 5 2.1. ISSUABLE IN SERIES 5 2.2. ESTABLISHMEN |
|
| November 16, 2018 |
Submission of Matters to a Vote of Security Holders 8-K 1 a8-k111418xasm.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2018 Cardiovascular Systems, Inc. (Exact name of Registrant as Specified in its Charter) Delaware 000-52082 41-1698056 (State or Other Jurisd |
|
| November 2, 2018 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 Commission File No. 000-52082 CARDIOVASCULAR SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware No. 41-1698056 (State or other jurisdic |
|
| November 2, 2018 |
Exhibit 10.7 THIRD LEASE AMENDMENT This Amendment (hereinafter “Third Lease Amendment”) is made as of the date set forth below between the Pearland Economic Development Corporation (“Landlord”) and Cardiovascular Systems, Inc., (“Tenant”) to amend those certain Lease Amendments (collectively, the “Lease Amendments”) incorporated by reference for all purposes, executed on November 10, 2017 and Apri |
|
| November 2, 2018 |
Separation Agreement, dated August 15, 2018, by and between the Company and Laurence L. Betterley Exhibit 10.1 August 15, 2018 Via Email Personal and Confidential Larry Betterley [ADDRESS REDACTED] Re: Separation Agreement and Release Dear Larry: As you know, your employment with Cardiovascular Systems, Inc. (“CSI”) will end effective at the close of business on August 15, 2018 (the “Separation Date”), due to your voluntary resignation. The purpose of this Separation Agreement and Release lett |
|
| November 2, 2018 |
Consulting Agreement, dated August 16, 2018, by and between the Company and Laurence L. Betterley EX-10.2 3 ex102consultingagreement-l.htm EXHIBIT 10.2 Exhibit 10.2 CONSULTING AGREEMENT EFFECTIVE DATE: August 16, 2018 PARTIES: Cardiovascular Systems, Inc. (“CSI”) 1225 Old Highway 8 NW St. Paul, MN 55112 Laurence L. Betterley (“Consultant”) [ADDRESS REDACTED] RECITAL: CSI and Consultant desire to enter into an arrangement by which Consultant will provide consulting services to CSI pursuant to t |
|
| October 30, 2018 |
Exhibit 99.1 CARDIOVASCULAR SYSTEMS, INC. REPORTS FISCAL 2019 FIRST-QUARTER FINANCIAL RESULTS Conference Call Scheduled for Today, October 30, 2018, at 3:45 PM CT (4:45 PM ET) • Revenues of $56.3 million increased 13.3% from first quarter last year • Net loss was $2.9 million, or $0.09 per basic and diluted share • Company reiterates fiscal year 2019 financial guidance • Company announces first co |
|
| October 30, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2018 Cardiovascular Systems, Inc. (Exact name of Registrant as Specified in its Charter) Delaware 000-52082 41-1698056 (State or Other Jurisdiction of Incorporation) (Comm |
|
| October 2, 2018 |
CSII / Cardiovascular Systems, Inc. DEFA14A DEFA14A 1 defa14a-2018.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant þ Filed by a Party other than the Registrant ¨ Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as per |
|
| October 2, 2018 |
Proxy Statement on Schedule 14A DEF 14A 1 def14a-2018.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant þ Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as perm |
|
| September 10, 2018 |
CSII / Cardiovascular Systems, Inc. / BROWN CAPITAL MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 2)* Cardiovascular Systems, Inc. (Name of Issuer) Common Stock, One-tenth of One Cent ($0.001) Par Value Per Share (Title of Class of Securities) 141619106 (C |
|
| August 23, 2018 |
Exhibit 10.26 CARDIOVASCULAR SYSTEMS, INC. EXECUTIVE OFFICER SEVERANCE PLAN Restatement Date: August 22, 2018 I. Introduction This document is the Cardiovascular Systems, Inc. Executive Officer Severance Plan (the “Plan”). (Cardiovascular Systems, Inc. is referred to as “the Company” in this document.) The purpose of severance pay is to help ease the financial burden resulting from the Executive O |
|
| August 23, 2018 |
Fiscal Year 2019 Executive Officer Base Salaries. Exhibit 10.4 FISCAL YEAR 2019 EXECUTIVE OFFICER BASE SALARIES The Company’s executive officers are scheduled to receive the following annual base salaries for the fiscal year ending June 30, 2019 in their current positions: Name/Title FY2019 Salary Scott R. Ward Chairman, President and Chief Executive Officer $ 670,000 Jeffrey S. Points Chief Financial Officer $ 302,500 Rhonda J. Robb Chief Operat |
|
| August 23, 2018 |
Fiscal 2019 Executive Officer Bonus Plan and Equity Compensation. Exhibit 10.5 FISCAL 2019 EXECUTIVE OFFICER BONUS PLAN AND EQUITY COMPENSATION Bonus Plan For the twelve month period ending June 30, 2019, each executive officer of Cardiovascular Systems, Inc. (the “Company”) is eligible to receive cash incentive compensation pursuant to the Fiscal 2019 Executive Officer Bonus Plan (the “Bonus Plan”) as follows: Revenue and Adjusted EBITDA Goals Receipt of cash i |
|
| August 23, 2018 |
Fiscal Year 2019 Director Compensation Arrangements. Exhibit 10.6 FISCAL 2019 DIRECTOR COMPENSATION ARRANGEMENTS For the 12 month period ending June 30, 2019, each non-employee director of Cardiovascular Systems, Inc. will receive the following compensation: ● Retainers of $45,000 for service as a Board member; $22,000 for service as the chair of the Audit committee; $20,000 for service as a chair of a Board committee other than the Audit committee; |
|
| August 23, 2018 |
Exhibit 10.57 SECOND LEASE AMENDMENT This Amendment (hereinafter “Amendment”) is made between the Pearland Economic Development Corporation (“Landlord”) and Cardiovascular Systems, Inc., (“Tenant”) to amend that certain Lease Amendment (the “Agreement”) attached hereto and incorporated by reference for all purposes, executed on November 10, 2017 between the Landlord and Tenant. I. Amended Terms. T |
|
| August 23, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2018 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-52082 CARDIOVASCULAR SYSTEMS, INC. (Exact name of registrant as speci |
|
| August 17, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2018 Cardiovascular Systems, Inc. (Exact name of Registrant as Specified in its Charter) Delaware 000-52082 41-1698056 (State or Other Jurisdiction of Incorporation) (Commi |
|
| July 31, 2018 |
CARDIOVASCULAR SYSTEMS, INC. AND AEROLASE CORP. SIGN COLLABORATIVE AGREEMENT FOR LASER ATHERECTOMY TECHNOLOGY St. Paul, Minn. – July 31, 2018 – Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced that it has signed an agreemen |
|
| July 31, 2018 |
ex992secanalystday2018 Analyst Day Meeting Scott R. Ward Chairman, President & CEO July 31, 2018 Safe Harbor FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Report Act of 1995, which are provided under the protection of the safe harbor for forward-looking statements provided by that Act. For example, statement |
|
| July 31, 2018 |
Financial Statements and Exhibits, Other Events 8-K 1 a8-k073118aerolaserelease.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2018 Cardiovascular Systems, Inc. (Exact name of Registrant as Specified in its Charter) Delaware 000-52082 41-1698056 (State or Other |
|
| July 30, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 a8-k73018.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2018 Cardiovascular Systems, Inc. (Exact name of Registrant as Specified in its Charter) Delaware 000-52082 41-1698056 (State or Other Jurisdiction of |
